EP Patent

EP1734920A2 — Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions

Assigned to Adamas Pharmaceuticals Inc · Expires 2006-12-27 · 19y expired

What this patent protects

This invention relates to methods and compositions comprising a NMDA receptor antagonist and an anti-depressive drug for treating psychiatric conditions, such as depression.

USPTO Abstract

This invention relates to methods and compositions comprising a NMDA receptor antagonist and an anti-depressive drug for treating psychiatric conditions, such as depression.

Drugs covered by this patent

Patent Metadata

Patent number: EP1734920A2
Jurisdiction: EP
Classification: —
Expires: 2006-12-27
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.